Group 1 - The company received a letter from Founder Securities regarding the replacement of the continuous supervision sponsor representative due to the departure of Mr. Cao Fangyi [1] - Mr. Jiang Zhuocheng has been appointed as the new sponsor representative to continue the supervision of the company's publicly issued convertible bonds [1] - The continuous supervision period will last until the obligations set by the China Securities Regulatory Commission and Shenzhen Stock Exchange are fulfilled [1] Group 2 - The board of directors expressed gratitude for Mr. Cao Fangyi's contributions during his tenure as the sponsor representative [2] - Mr. Jiang Zhuocheng holds a Master's degree in International Business from Southwest University of Finance and Economics and has extensive experience in investment banking since 2021 [3] - His qualifications include being a registered accountant, registered tax agent, and holding a legal professional qualification [3]

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-29 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 公司董事会对曹方义先生在担任公司保荐代表人及持续督导期间所做出的 贡献表示衷心的感谢！ 特此公告。 奥佳华智能健康科技集团股份有限公司 董 事 会 2025 年 7 月 21 日 附件：保荐代表人蒋卓成先生简历 蒋卓成：西南财经大学国际商务硕士，保荐代表人，取得注册会计师、注册 税务师、法律职业资格。2021 年开始从事投资银行业务，先后主持或参与了索 通发展（603612.SH）、中矿资源（002738.SZ）非公开发行，甬矽电子（688362.SH） IP0，梦网科技（002123.SZ）重大资产重组，具有丰富的投资银行业务从业经验。 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）于今日收到方 正证券承销保荐有限责任公司（以下简 ...

Core Viewpoint - The foot massage device industry is experiencing growth driven by increasing health awareness, an aging population, and technological advancements, with the market size expected to reach 446 million yuan in 2024, a year-on-year increase of 6.01% [1][11]. Industry Overview - Foot massage devices are designed to stimulate and relax foot muscles and acupoints, improving fatigue relief, sleep quality, and blood circulation [3][11]. - The industry is supported by a growing elderly population in China, providing a substantial user base for foot massage devices [1][11]. Market Dynamics - The rapid development of e-commerce has made online sales channels a significant direction for foot massage device sales, with platforms like JD.com, Tmall, and Douyin being major contributors [9]. - The e-commerce transaction volume in China is projected to grow from 33.87 trillion yuan in 2019 to 46.41 trillion yuan in 2024, benefiting the foot massage device industry [9]. Competitive Landscape - The foot massage device industry features a diverse competitive landscape, including international brands like Panasonic and domestic leaders such as Beileisong, Aojiahua, and Rongtai Health, alongside numerous small and medium enterprises [13][14]. Industry Chain - The industry chain consists of upstream suppliers providing components and materials, midstream manufacturers producing various types of foot massage devices, and downstream sales channels including online platforms and physical stores [6]. Development Trends - Future trends in the foot massage device industry include the integration of smart features for personalized health monitoring and remote medical guidance [18]. - Customization services are emerging to meet the diverse needs of different consumer groups, enhancing user satisfaction and product competitiveness [19]. Market Demand - There is a growing recognition of proactive health management, leading to increased demand for foot massage devices as tools for muscle relaxation and blood circulation improvement [21].

Core Viewpoint - OgaHua is facing significant challenges in its business performance, particularly in the massage chair segment, with declining revenues and increasing operational pressures due to reliance on overseas markets and changing consumer demand [1][2][3]. Financial Performance - OgaHua's revenue has declined from approximately 60.24 billion in 2022 to about 50.3 billion in 2023, with Q1 2023 revenue at around 10.51 billion, representing an 11.15% year-on-year decrease [1][2]. - The company reported a net profit of approximately 499.7 million in Q1 2023, largely due to non-operating income, while the adjusted net profit showed a loss of about 996 million, marking the first loss in three years [2]. Market Dynamics - The massage chair market is currently facing a downturn, with OgaHua lagging behind competitors like Rongtai Health, which reported a slight revenue increase of 3.86% in Q1 2023 [2]. - OgaHua's international sales accounted for 68.94% of its total revenue, with significant reliance on markets in Europe, North America, and Southeast Asia, which are currently experiencing weak demand [2][3]. Strategic Initiatives - OgaHua plans to expand its market presence in countries along the "Belt and Road" initiative and enhance its cross-border e-commerce channels to mitigate current challenges [4]. - The company is also focusing on diversifying its product offerings beyond massage chairs to include health-related appliances, which previously helped maintain revenue during the pandemic [6]. Operational Challenges - The marketing pressure for massage chairs is high due to their non-essential nature and high price points, leading to longer consumer decision-making processes [5]. - OgaHua is reducing operational costs, with sales expenses down by 2.47% and R&D expenses down by 9.57% in 2023, indicating a need to manage financial strain amid declining revenues [4].

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering conditions for a downward adjustment due to stock prices falling below 85% of the current conversion price [2][6][15] Group 1: Board Meeting and Decisions - The sixth board meeting was held on July 4, 2025, where all nine directors participated and confirmed the meeting's legitimacy [1][2] - The board unanimously approved the proposal not to adjust the conversion price of the "Aojia Convertible Bonds" [2][6] Group 2: Convertible Bond Details - The current conversion price of the "Aojia Convertible Bonds" is 9.35 yuan per share, and the stock price has been below 7.95 yuan for fifteen consecutive trading days, triggering the adjustment clause [6][15] - The company issued 12 million convertible bonds on February 25, 2020, with a total value of 120 million yuan [6][8] - The bonds were listed on the Shenzhen Stock Exchange on March 18, 2020, under the code "128097" [7] Group 3: Conversion Price Adjustment History - The conversion price has been adjusted multiple times due to profit distribution, with the most recent adjustment reducing the price from 9.45 yuan to 9.35 yuan on May 29, 2025 [10][12] - The company has a defined process for adjusting the conversion price, which requires board approval and shareholder voting [13][14]

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-28 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 关于不向下修正奥佳转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 7 月 4 日，公司股票已有十五个交易日的收盘价低于当期转 股价格 9.35 元/股的 85%的情形，已触发"奥佳转债"转股价格的向下修正条件。 2、公司于 2025 年 7 月 4 日召开第六届董事会第九次会议，审议通过了《关 于不向下修正"奥佳转债"转股价格的议案》，公司董事会决定本次不向下修正 "奥佳转债"转股价格，且在未来六个月内（即 2025 年 7 月 5 日至 2026 年 1 月 4 日），如再次触发"奥佳转债"转股价格向下修正条款，亦不提出向下修正 方案。从 2026 年 1 月 5 日重新起算，若再次触发"奥佳转债"转股价格向下修 正条款，届时公司董事会将再次召开会议决定是否行使" ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-27 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 2、关于不向下修正奥佳转债转股价格的公告。 特此公告。 奥佳华智能健康科技集团股份有限公司 董 事 会 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）第六届董事会第 九次会议通知以电话、传真及电子邮件等相结合方式于 2025 年 7 月 4 日发出。会 议于 2025 年 7 月 4 日下午 15:30 在厦门市湖里区安岭二路 31-37 号公司八楼会议室 以通讯的方式召开，并获得全体董事确认。本次会议应到董事 9 名，通讯出席本次 会议董事 9 名。公司部分监事、高管列席了本次会议。本次会议为情况紧急召开的 董事会临时会议，召集人已在会议上作出相关说明。本次会议由公司董事长邹剑寒 先生主持，会议符合《中华人民共和国公司法》和公司章程 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-26 号 | | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | 奥佳华智能健康科技集团股份有限公司 股票代码：002614 股票简称：奥佳华 债券代码：128097 债券简称：奥佳转债 转股价格：人民币 9.35 元/股 转股日期：2020 年 9 月 2 日至 2026 年 2 月 25 日 （一）可转债发行情况 经中国证券监督管理委员会证监许可【2019】1966 号文核准，公司于 2020 年 2 月 25 日公开发行了 1,200 万张可转换公司债券，每张面值 100 元，发行总 额 120,000.00 万元。本次公开发行的可转债向公司在股权登记日收市后登记在册 的原股东优先配售，原股东优先配售后余额部分（含原股东放弃优先配售部分） 通过深圳证券交易所交易系统网上向社会公众投资者发行。认购不足 120,000.00 万元的部分由主承销商余额包销。 2025 年第二季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述 ...

Core Viewpoint - The company, Aojiahua Intelligent Health Technology Group Co., Ltd., has announced a potential downward adjustment of the conversion price for its convertible bonds, "Aojia Convertible Bonds," due to the stock price falling below a certain threshold [2][12]. Group 1: Convertible Bond Issuance and Adjustment - The company issued 12 million convertible bonds with a total value of 120 million yuan, approved by the China Securities Regulatory Commission [3]. - The bonds were listed on the Shenzhen Stock Exchange on March 18, 2020, with a conversion price initially set at 10.89 yuan per share [4]. - The conversion price has been adjusted multiple times due to profit distribution, with the latest adjustment bringing it down to 9.35 yuan per share effective from May 29, 2025 [8]. Group 2: Conditions for Price Adjustment - The company may adjust the conversion price downwards if the stock price remains below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [10]. - If the conditions are met, the board will convene to decide on the adjustment and disclose the decision accordingly [11]. Group 3: Recent Developments - As of June 16, 2025, the stock price has been below the threshold of 7.95 yuan per share, indicating a potential trigger for the conversion price adjustment [12]. - The board has previously decided not to adjust the conversion price for a six-month period starting from December 14, 2024 [12].

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-25 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 关于奥佳转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 股票代码：002614 股票简称：奥佳华 债券代码：128097 债券简称：奥佳转债 转股价格：人民币 9.35 元/股 转股日期：2020 年 9 月 2 日至 2026 年 2 月 25 日 自 2025 年 6 月 16 日至 2025 年 6 月 27 日，公司股票已有 10 个交易日的收 盘价低于当期转股价格的 85%，预计将有可能触发"奥佳转债"转股价格向下修 正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股 价格，并及时履行信息披露义务。敬请广大投资者注意投资风险。 一、可转债发行上市情况及转股价格调整情况 （一）可转债发行情况 经中国证券监督管理委员会证监许可【2019】 ...